Jacqueline Palace

Active 1997–2025

204
Papers
30,460
Citations
96
h-index
193
i10-index

Citations

Citations per year for Jacqueline Palace1990: 1 citations1997: 2 citations1998: 1 citations2000: 9 citations2001: 11 citations2002: 24 citations2003: 36 citations2004: 32 citations2005: 39 citations2006: 39 citations2007: 50 citations2008: 68 citations2009: 67 citations2010: 77 citations2011: 104 citations2012: 117 citations2013: 159 citations2014: 169 citations2015: 214 citations2016: 204 citations2017: 216 citations2018: 292 citations2019: 971 citations2020: 1,330 citations2021: 1,228 citations2022: 1,097 citations2023: 1,011 citations2024: 1,725 citations2025: 668 citations2026: 15 citations1991–1996: no citations, so these years are not shown1999: no citations, so this year is not shown

Citation sources

Countries

World map of the countries and regions citing this authorUnited States: 1,850 citing papers, 19.3% of this breakdownUnited Kingdom: 975 citing papers, 10.2% of this breakdownGermany: 808 citing papers, 8.4% of this breakdownItaly: 744 citing papers, 7.7% of this breakdownChina: 584 citing papers, 6.1% of this breakdownCanada: 406 citing papers, 4.2% of this breakdownFrance: 386 citing papers, 4% of this breakdownSpain: 351 citing papers, 3.7% of this breakdownNetherlands: 326 citing papers, 3.4% of this breakdownJapan: 283 citing papers, 2.9% of this breakdownSwitzerland: 272 citing papers, 2.8% of this breakdownAustria: 255 citing papers, 2.7% of this breakdown
0%19.3%Other 24.6%

Fields

  • Medicine83.2%
  • Biochemistry, Genetics and Molecular Biology6.6%
  • Neuroscience5.6%
  • Immunology and Microbiology2.2%
  • Computer Science0.8%
  • Engineering0.6%
  • Other1%

Topics

  • Multiple Sclerosis Research Studies19.6%
  • Peripheral Neuropathies and Disorders11.5%
  • Myasthenia Gravis and Thymoma4.9%
  • Autoimmune Neurological Disorders and Treatments3.9%
  • Systemic Lupus Erythematosus Research3.2%
  • Neuroinflammation and Neurodegeneration Mechanisms2.5%
  • Other54.4%

Coauthors

All papers

Open in search
  1. Diagnosis of myelin oligodendrocyte glycoprotein antibody-associated disease: International MOGAD Panel proposed criteria

    Authors: , , , , , , , , , , , , , , , , , , , , , , - The Lancet Neurology 2023 cited by 1,130

  2. Myasthenia gravis

    Authors: , , , , , - Nature Reviews Disease Primers 2019 cited by 899

  3. 2021 MAGNIMS–CMSC–NAIMS consensus recommendations on the use of MRI in patients with multiple sclerosis

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Franz Fazekas, Massimo Filippi, Jette Lautrup Frederiksen, Claudio Gasperini, Yael Hacohen, Ludwig Kappos, Kshitij Mankad, Xavier Montalbán, Jacqueline Palace, Maria A. Rocca, Jaume Sastre‐Garriga, Mar Tintoré, Hugo Vrenken, Tarek Yousry, Frederik Barkhof, Àlex Rovira, David K.B. Li, Anthony Traboulsee, Scott D. Newsome, Brenda Banwell, Jiwon Oh, Daniel S. Reich, Daniel S. Reich, Jiwon Oh - The Lancet Neurology 2021 cited by 643

  4. International Consensus Guidance for Management of Myasthenia Gravis

    Authors: , , , , , , , , , , , , , , , - Neurology 2020 cited by 725

  5. International consensus guidance for management of myasthenia gravis

    Authors: , , , , , , , , , , , , , , - Neurology 2016 cited by 1,138

  6. Myelin-oligodendrocyte glycoprotein antibody-associated disease

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Krzysztof Selmaj, Aksel Sıva, Bruno Stankoff, Mar Tintoré, Anthony Traboulsee, Patrick Waters, Emmanuelle Waubant, Brian G. Weinshenker, Tobias Derfuß, Sandra Vukusic, Bernhard Hemmer - The Lancet Neurology 2021 cited by 517

  7. Eculizumab in Aquaporin-4–Positive Neuromyelitis Optica Spectrum Disorder

    Authors: , , , , , , , , , , , , , , - New England Journal of Medicine 2019 cited by 846

  8. Trial of Satralizumab in Neuromyelitis Optica Spectrum Disorder

    Authors: , , , , , , , , , , , , - New England Journal of Medicine 2019 cited by 642

  9. Clinical presentation and prognosis in MOG-antibody disease: a UK study

    Authors: , , , , , , , , , , , , , , , , - Brain 2017 cited by 730

  10. MRI criteria for the diagnosis of multiple sclerosis: MAGNIMS consensus guidelines

    Authors: , , , , , , , , , , , , , , , - The Lancet Neurology 2016 cited by 863

  11. Ravulizumab in Aquaporin‐4–Positive Neuromyelitis Optica Spectrum Disorder

    Authors: , , , , , , , , , , , , , , - Annals of Neurology 2023 cited by 191

  12. Epidemiology of Neuromyelitis Optica Spectrum Disorder and Its Prevalence and Incidence Worldwide

    Authors: , , , , , , , , , , , , , , , - Frontiers in Neurology 2020 cited by 398

  13. MOG encephalomyelitis: international recommendations on diagnosis and antibody testing

    Authors: , , , , , , , , , , , , , , , , , , - Journal of Neuroinflammation 2018 cited by 738

  14. Worldwide Incidence and Prevalence of Neuromyelitis Optica

    Authors: , , , , , , , , , , , , , , , - Neurology 2020 cited by 299

  15. International multicenter examination of MOG antibody assays

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , - Neurology Neuroimmunology & Neuroinflammation 2020 cited by 278

  16. Disease Course and Treatment Responses in Children With Relapsing Myelin Oligodendrocyte Glycoprotein Antibody–Associated Disease

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , - JAMA Neurology 2018 cited by 415

  17. International Delphi Consensus on the Management of AQP4-IgG+ NMOSD

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , - Neurology Neuroimmunology & Neuroinflammation 2023 cited by 86

  18. MRI characteristics of neuromyelitis optica spectrum disorder

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Dean Wingerchuk, Ho Jin Kim, Lekha Pandit, Ilya Kister, Maria Isabel Leite, Jacqueline Palace, Metha Apiwattanakul, Ingo Kleiter, Naraporn Prayoonwiwat, May Han, Kerstin Hellwig, Brenda Banwell, Katja Van Herle, Jacinta M. Behne, Gareth John, D. Craig Hooper, Kazuo Fujihara, Ichiro Nakashima, Douglas Kazutoshi Sato, Anthony Traboulsee, Michael R. Yeaman, Emmanuelle Waubant, Scott Zamvil, Jeffrey L. Bennett, Marco Aurélio Lana–Peixoto, Benjamin Greenberg, Olaf Stüve, Orhan Aktaş, Jens Wuerfel, Terry J. Smith, Nasrin Asgari, Anu Jacob, Kevin C. O’Connor - Neurology 2015 cited by 650

  19. Multicentre comparison of a diagnostic assay: aquaporin-4 antibodies in neuromyelitis optica

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Mark Woodhall, Jacqueline Palace, Friedemann Paul, Hans-Peter Hartung, Orhan Aktaş, Sven Jarius, Brigitte Wildemann, Christian A. Vedeler, Anne Ruiz, Maria Isabel Leite, Peter Trillenberg, Monika Probst, Sandra Saschenbrecker, Angela Vincent, Romain Marignier - Journal of Neurology Neurosurgery & Psychiatry 2016 cited by 296

  20. Factors Associated With Relapse and Treatment of Myelin Oligodendrocyte Glycoprotein Antibody–Associated Disease in the United Kingdom

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , - JAMA Network Open 2022 cited by 118

  21. Advances and ongoing research in the treatment of autoimmune neuromuscular junction disorders

    Authors: , , , , , - The Lancet Neurology 2022 cited by 108

  22. Outcome prediction models in AQP4-IgG positive neuromyelitis optica spectrum disorders

    Authors: , , , , , , , , , , , , , , , , , - Brain 2019 cited by 205

  23. Performance of the 2017 and 2010 Revised McDonald Criteria in Predicting MS Diagnosis After a Clinically Isolated Syndrome

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Jaume Sastre‐Garriga, Tarek Yousry - Neurology 2021 cited by 80

  24. Long-term Efficacy of Satralizumab in AQP4-IgG–Seropositive Neuromyelitis Optica Spectrum Disorder From SAkuraSky and SAkuraStar

    Authors: , , , , , , , , , , , - Neurology Neuroimmunology & Neuroinflammation 2022 cited by 66